Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T cells in advanced multiple myeloma
NCT03338972Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2017
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FCARH143 in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Started Nov 2017; status: completed.
02
Drugs
FCARH143
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03338972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338972.